Poster Schedule

7:00 AM – 5:00 PM MST

(M-001) Direct and Indirect Exposure-Response Modeling for Transthyretin Amyloid Cardiomyopathy Treated with Acoramidis

7:00 AM – 5:00 PM MST

(M-002) A Longitudinal Model-based Meta-Analysis (MBMA) of Body Weight in Obesity Trials

7:00 AM – 5:00 PM MST

(M-003) Determining an Appropriate Fosfomycin Dosing Regimen in Pneumonia Patients by Utilizing minimal PBPK Modeling and Target Attainment Analysis

Favorite

7:00 AM – 5:00 PM MST

(M-004) MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.

Favorite

7:00 AM – 5:00 PM MST

(M-005) Coupling A Quantitative Systems Pharmacology Model With A Simple Statistical Layer To Predict Asthma Exacerbation Rate Reduction From Allergen Challenge Results

Favorite

7:00 AM – 5:00 PM MST

(M-006) An innovative paradigm for non-small cell lung cancer clinical trial simulations through the Integration of a quantitative systemic pharmacology model and pharmacodynamic model of gemcitabine

Favorite

7:00 AM – 5:00 PM MST

(M-007) Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study

Favorite

7:00 AM – 5:00 PM MST

(M-008) A within-host dynamic model of Bordetella pertussis to support vaccine development

Favorite

7:00 AM – 5:00 PM MST

(M-009) Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC

Favorite

7:00 AM – 5:00 PM MST

(M-010) Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216

Favorite

7:00 AM – 5:00 PM MST

(M-011) A Survey of Model Informed Approaches in Neuroscience Drug Development

Favorite

7:00 AM – 5:00 PM MST

(M-012) Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program

Favorite

7:00 AM – 5:00 PM MST

(M-013) Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.

Favorite

7:00 AM – 5:00 PM MST

(M-014) A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model

Favorite

7:00 AM – 5:00 PM MST

(M-015) Intranasal Diamorphine Population Pharmacokinetics Modeling and Simulation in Pediatric Breakthrough Pain

Favorite

7:00 AM – 5:00 PM MST

(M-016) Integrating Physiologically Based Pharmacokinetic Modeling with Machine Learning for the Rational Design of Nanoparticles to Improve Safety in Biomedical Applications

Favorite

7:00 AM – 5:00 PM MST

(M-017) A Semi-mechanistic Pharmacokinetic-Pharmacodynamic/Toxicodynamic Model to Guide Dose Optimization of Combination Therapies Targeting DNA Damage Response Pathways

Favorite

7:00 AM – 5:00 PM MST

(M-018) Population Pharmacokinetic Assessment of Guselkumab in Adults with Moderately to Severely Active Ulcerative Colitis

Favorite

7:00 AM – 5:00 PM MST

(M-019) Predictors Of Insulin Dose In Individuals With New-Onset Type 1 Diabetes

Favorite

7:00 AM – 5:00 PM MST

(M-020) Dissecting Bcl-2 Sensitivity In Acute Myeloid Leukemia: A Quantitative Systems Pharmacology Model For Venetoclax-Azacitidine Therapy

Favorite

7:00 AM – 5:00 PM MST

(M-021) Towards A Computational QSP Platform To Support Antibody Drug Conjugate Design In Cancer

Favorite

7:00 AM – 5:00 PM MST

(M-022) Towards A QSP Platform To Support Drug Development In Hematological Cancers

Favorite

7:00 AM – 5:00 PM MST

(M-023) Evaluating the Importance of Glucagon in the Insulin-Glucose Regulatory System: A Mechanistic Modeling Approach

Favorite

7:00 AM – 5:00 PM MST

(M-024) Mechanistic Translational Modeling Versus Minimal Anticipated Biological Effect Level Approach to Predict First-in-human Dose For T-cell Engagers: HPN536 Case Study.

Favorite

7:00 AM – 5:00 PM MST

(M-025) A quantitative systems pharmacology (QSP) model to enable prediction of ARIA-E incidence with anti-Aβ monoclonal antibody therapies for Alzheimer’s disease

Favorite

7:00 AM – 5:00 PM MST

(M-026) Augmented Definitive Screening Design Provides Efficient Phase 1 Selection of CAR T-cell and Lymphodepletion Regimen

Favorite

7:00 AM – 5:00 PM MST

(M-027) Model-based meta-analysis of safety for monomethyl auristatin E-conjugated antibody drug conjugates in cancer patients

Favorite

7:00 AM – 5:00 PM MST

(M-028) A systematic approach for imputing missing dose information in population pharmacokinetic analysis datasets

Favorite

7:00 AM – 5:00 PM MST

(M-029) Bilirubin Elevation Due To Atazanavir Treatment May Primarily Be Mediated By Inhibition Of OATP1B1/3 Rather Than That Of UGT1A1: PBPK Analysis Of Bilirubin-Atazanavir-Polymorphism Interaction

Favorite

7:00 AM – 5:00 PM MST

(M-030) A Minimal QSP Model for Treg Responses of IL-2 Mutein MK-6194 – A Conceptual Model for Autoimmune Disease

Favorite

7:00 AM – 5:00 PM MST

(M-031) Development and application of a mechanistic model for Alzheimer’s Disease

Favorite

7:00 AM – 5:00 PM MST

(M-032) A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron

Favorite

7:00 AM – 5:00 PM MST

(M-033) babelmixr2 and PopED: Quick Conversion of NONMEM, Monolix and nlmixr2/rxode2 Models to PopED Optimal Design Analysis

Favorite

7:00 AM – 5:00 PM MST

(M-034) Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models

Favorite

7:00 AM – 5:00 PM MST

(M-035) PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody

Favorite

7:00 AM – 5:00 PM MST

(M-036) Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic

Favorite

7:00 AM – 5:00 PM MST

(M-037) K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia

Favorite

7:00 AM – 5:00 PM MST

(M-038) K-PD Modeling of Plozasiran - Mixed Hyperlipidemia

Favorite

7:00 AM – 5:00 PM MST

(M-039) A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome

Favorite

7:00 AM – 5:00 PM MST

(M-040) Novel endpoints based on tumor growth dynamics – A comprehensive simulation study with retrospective validation

Favorite

7:00 AM – 5:00 PM MST

(M-041) Exploring Best Practices of the Population Pharmacokinetic Modeling for Antibody-Drug Conjugates – a Simulation Study

Favorite

7:00 AM – 5:00 PM MST

(M-042) Model-Informed Dose Justifications and Clinical Pharmacology Strategy of Posaconazole in Japanese Patients for Prophylaxis and Treatment Against Fungal Infection

Favorite

7:00 AM – 5:00 PM MST

(M-043) Image Processing with Spatial Modeling of Neural Tissue: A New Approach to Pharmacokinetic Analysis

Favorite

7:00 AM – 5:00 PM MST

(M-044) MIDD Platform of VZV Vaccine Immunogenicity and Efficacy

Favorite

7:00 AM – 5:00 PM MST

(M-045) Visual predictive check of longitudinal models and dropout

Favorite

7:00 AM – 5:00 PM MST

(M-046) Development and Application of Inavolisib Physiologically-based Pharmacokinetic (PBPK) Model for Drug-drug Interaction (DDI) Assessment

Favorite

7:00 AM – 5:00 PM MST

(M-047) Population Pharmacokinetics of Nivolumab in Patients with Newly Diagnosed or Relapsed/Refractory Classical Hodgkin Lymphoma

Favorite

7:00 AM – 5:00 PM MST

(M-048) mipdtrial: an open-source R package for simulating model-informed precision dosing trials

Favorite

7:00 AM – 5:00 PM MST

(M-049) Disease Progression Modeling of Stargardt’s disease

Favorite

7:00 AM – 5:00 PM MST

(M-050) Exposure-Response Analysis of Cenobamate

Favorite

7:00 AM – 5:00 PM MST

(M-051) The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM

Favorite

7:00 AM – 5:00 PM MST

(M-052) Accounting For Dose Modifications In Exposure-Response Analyses In Oncology: The Case Example Of Brigimadlin

Favorite

7:00 AM – 5:00 PM MST

(M-053) PKPD modeling and simulation of an inhaled antibiotic targeting Gram-negative bacteria, using a bacteriophage-derived endolysin.

Favorite

7:00 AM – 5:00 PM MST

(M-054) Preclinical data exposures underpredict clinical physiologically active doses for bispecific TCEs in solid tumors indications; are there better metrics? - insights from a small mechanistic MBMA

Favorite

7:00 AM – 5:00 PM MST

(M-055) Immune Correlates of Protection against Respiratory Syncytial Virus Infection and an Application to Model-Informed Vaccine Development for an internal compound: a Model-Based Meta-Analysis

Favorite

7:00 AM – 5:00 PM MST

(M-056) A Translational Quantitative Systems Pharmacology (QSP) Modeling Framework to Predict Interleukin-15 (IL-15) Cytokine Levels in Multiple Myeloma Patients after Anti-BCMA CAR-NK Cell Therapy

Favorite

7:00 AM – 5:00 PM MST

(M-057) A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model

Favorite

7:00 AM – 5:00 PM MST

(M-058) Pharmacokinetic/Pharmacodynamic Modeling for Dose Selection of S-001, a Novel mRNA-based Therapy for Pancreatic Cancer

Favorite

7:00 AM – 5:00 PM MST

(M-059) Physiologically based pharmacokinetic (PBPK) modeling of methotrexate in cerebrospinal fluid in humans

Favorite

7:00 AM – 5:00 PM MST

(M-060) Impact of Drug Interactions and Genetic Variability on High-Dose Methotrexate in Children with Acute Lymphoblastic Leukemia

Favorite

7:00 AM – 5:00 PM MST

(M-061) A clinical trial simulator tool for a randomized delayed start trial in Parkinson’s disease

Favorite

7:00 AM – 5:00 PM MST

(M-062) Successful Dose Optimization and Recommended Phase III Dose Determination of Saruparib (PARP1 Selective Inhibitor) Through MIDD and Comprehensive Quantitative Clinical Pharmacology

Favorite

7:00 AM – 5:00 PM MST

(M-063) Population Pharmacokinetic/Pharmacodynamic Analysis of YH35995 for the First-in-Human Dose Prediction

Favorite

7:00 AM – 5:00 PM MST

(M-064) A semi-mechanistic pharmacometrics model to quantitatively characterize delta-9-tetrahydrocannabinol (THC) and its metabolites’ disposition among oral cannabis users

Favorite

7:00 AM – 5:00 PM MST

(M-065) Decoding Mean Viral Load in RSV Human Challenge Studies

Favorite

7:00 AM – 5:00 PM MST

(M-066) Optimizing Clinical Translation of Bispecific T Cell Engagers through Context Unification with a Quantitative Systems Pharmacology Model

Favorite

7:00 AM – 5:00 PM MST

(M-067) Stochastic Simulation and Estimation (SSE) for Design of Sample Size and Time Points in Pediatric Studies

Favorite

7:00 AM – 5:00 PM MST

(M-068) A translational QSP model to characterize the preclinical pharmacodynamics of combining a KRAS G12C inhibitor with a SHP2 inhibitor

Favorite

7:00 AM – 5:00 PM MST

(M-070) Model Informed Drug Development (MIDD) Approach to Support Elzovantinib (TPX-022) Recommended Phase 2 Dose

Favorite

7:00 AM – 5:00 PM MST

(M-071) Mechanistic mathematical model of emicizumab

Favorite

7:00 AM – 5:00 PM MST

(M-072) A shared pool modeling approach to describe antibody-mediated cell-cell interactions

Favorite

7:00 AM – 5:00 PM MST

(M-073) A Scalable Cloud-Based QSP Modeling System for Virtual Patient Generation

Favorite

7:00 AM – 5:00 PM MST

(M-074) Exposure-efficacy analysis of datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate, in patients with advanced non-small cell lung cancer

Favorite

7:00 AM – 5:00 PM MST

(M-075) Leveraging Digital Biomarkers to Enhance Clinical Pharmacology and Pharmacometrics Informed Drug Development: A Case Study

Favorite

7:00 AM – 5:00 PM MST

(M-076) Methodology of the Exposure-Response (E-R) Analysis of Linvoseltamab in Patients with Relapsed/Refractory (RR) Multiple Myeloma (MM)

Favorite

7:00 AM – 5:00 PM MST

(M-077) Population Pharmacokinetic Analysis of Fenebrutinib in Patients with Relapsing Multiple Sclerosis

Favorite

7:00 AM – 5:00 PM MST

(M-078) PKPD Modeling of PROTACs

Favorite

7:00 AM – 5:00 PM MST

(M-079) Advancing Drug Development Strategies in Progressive Supranuclear Palsy: A Model-based Clinical Trial Simulation Tool Approach

Favorite

7:00 AM – 5:00 PM MST

(M-080) Development of a Simeprevir PBPK Model to Describe Changes in Coproporphyrin-I, an Endogenous OATP1B Biomarker, in Subjects with HCV

Favorite

7:00 AM – 5:00 PM MST

(M-081) Population Pharmacokinetic and Exposure-Response Analyses of Valbenazine in Patients with Huntington’s Disease Chorea

Favorite

7:00 AM – 5:00 PM MST

(M-082) Integration of pharmacokinetics, safety, and efficacy into model-informed dose selection for Pimicotinib

Favorite

7:00 AM – 5:00 PM MST

(M-083) Assessing Parameter Impacts on ADC Efficacy and Toxicity: Capabilities and Limitations of Sensitivity Analysis in an Innovative Full Physiologically Based Pharmacokinetic Pharmacodynamic Framework

Favorite

7:00 AM – 5:00 PM MST

(M-084) Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Burosumab in Patients with X-Linked Hypophosphatemia Aged <12 Months

Favorite

7:00 AM – 5:00 PM MST

(M-085) PBPK-mQSP Model Analysis of KHK4951, an Eye Drop Formulation of Tivozanib, a Potent and Selective VEGF Receptor Inhibitor

Favorite

7:00 AM – 5:00 PM MST

(M-086) Population Pharmacokinetic (Pop PK) Modeling of Nirmatrelvir/Ritonavir in Severe Renal Impaired Participants with COVID-19 either on or not on Hemodialysis

Favorite

7:00 AM – 5:00 PM MST

(M-087) Model Platform to Predict Long-Term Clinical Outcome for Patients with Relapsed and Refractory Multiple Myeloma (RRMM)

Favorite

7:00 AM – 5:00 PM MST

(M-088) Modeling Effects of Dose, Schedule, and Pharmacokinetics of Fludarabine Lymphodepletion Therapy on CAR T-cell and Cytokine Dynamics

Favorite

7:00 AM – 5:00 PM MST

(M-089) A minimal PBPK model to study the effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody PK

Favorite

7:00 AM – 5:00 PM MST

(M-090) A Novel Approach to Capturing the Dynamics of Nontarget and New Tumors in Mechanistic Models of Progression-Free Survival

Favorite

7:00 AM – 5:00 PM MST

(M-091) Fully Bayesian Covariate Selection in Population Pharmacokinetics and Pharmacodynamics Models Using Regularized Horseshoe Priors

Favorite

7:00 AM – 5:00 PM MST

(M-092) Integrated Quantitative Systems Pharmacology and Pharmacometric Model to Evaluate Effective Buprenorphine Induction Treatment Strategies in the Era of Synthetic Opioids

Favorite

7:00 AM – 5:00 PM MST

(M-093) Challenges in curating Real World Data for modeling: A Bronchopulmonary Dysplasia case study

Favorite

7:00 AM – 5:00 PM MST

(M-095) Population Pharmacokinetic Modeling Informed the Dose of GDC-8264 for a Phase 1b Study in Participants with Acute Graft-Versus-Host Disease

Favorite

7:00 AM – 5:00 PM MST

(M-096) Population pharmacokinetics analysis of DA-8010, a novel anti-muscarinic agent

Favorite

7:00 AM – 5:00 PM MST

(M-097) Automatic differentiation, a possible solution to numerical instability in Population PK parameter estimation

Favorite

7:00 AM – 5:00 PM MST

(M-098) Population pharmacokinetic modeling of TBA-7371 in healthy participants describes apparent auto-induction of clearance and predicts PK of participants with Mycobacterium tuberculosis

Favorite

7:00 AM – 5:00 PM MST

(M-099) Advancing Drug Development in Relapsed and Refractory Multiple Myeloma (RRMM): Assessing the Safety and Efficacy Landscape Utilizing Model-Based Meta-Analysis

Favorite

7:00 AM – 5:00 PM MST

(M-100) A Quantitative Systems Pharmacology Model of LNP-mRNA Uptake Through LDLR Binding

Favorite

7:00 AM – 5:00 PM MST

(M-101) Cardiovascular Model Parameterization of Digital Twins for Acute Care Drug Delivery: An Iterative Bayesian Approach

Favorite

7:00 AM – 5:00 PM MST

(M-102) Population Pharmacokinetics and Exposure-Response Analysis of Birociclib Plus Fulvestrant in Advanced Breast Cancer Patients

Favorite

7:00 AM – 5:00 PM MST

(M-103) Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM

Favorite

7:00 AM – 5:00 PM MST

(M-104) Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model

Favorite

7:00 AM – 5:00 PM MST

(M-105) Sex differences in patients with chronic kidney disease: A quantitative systems pharmacology modeling study

Favorite

7:00 AM – 5:00 PM MST

(M-106) A Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies

Favorite

7:00 AM – 5:00 PM MST

(M-107) Physiologically-Based Pharmacokinetic Modeling of Maribavir Incorporating Metabolism by Cytochrome P450, Glucuronidation, and Hepatic Uptake, for Prediction of Victim Drug-Drug Interaction Potentials

Favorite

7:00 AM – 5:00 PM MST

(M-108) How should we leverage prior adult knowledge for pediatric PK analysis? - A case study comparing Pooled and Bayesian population PK approaches

Favorite

7:00 AM – 5:00 PM MST

(M-109) Advancing Quantitative Systems Pharmacology Model for Inflammatory Bowel Disease for Clinical Efficacy Predictions in Ulcerative Colitis

Favorite

7:00 AM – 5:00 PM MST

(M-110) A quantitative systems pharmacology model for diabetes-induced glomerular fibrosis

Favorite

7:00 AM – 5:00 PM MST

(M-111) Cystatin C complements but does not exceed serum creatinine as a renal function marker: evidence from vancomycin pharmacokinetic model performance in a clinical context

Favorite

7:00 AM – 5:00 PM MST

(M-112) Evaluation of Praziquantel Exposures in Children Dosed Using Different Body Weight Estimation Methods

Favorite

7:00 AM – 5:00 PM MST

(M-113) Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials

Favorite

7:00 AM – 5:00 PM MST

(M-114) Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients

Favorite

7:00 AM – 5:00 PM MST

(M-115) Population Pharmacokinetic and Exposure-Response Analyses of Tasurgratinib in Subjects with Unresectable Advanced or Metastatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 Gene Fusion

Favorite

7:00 AM – 5:00 PM MST

(M-116) Approaches of Incorporating Prior Information in Pediatric PopPK Model Development with Limited Data

Favorite

7:00 AM – 5:00 PM MST

(M-117) Semi-mechanistic modeling to investigate differential dynamics of anti-citrullinated protein antibody (ACPA) IgG versus total IgG reduction following nipocalimab treatment

Favorite

7:00 AM – 5:00 PM MST

(M-118) Past as Prologue: A Novel Anti-Fucosyl-GM1 Monoclonal Antibody in Extended Stage Small Cell Lung Cancer (ES-SCLC) Phase 3 Dose Selection through Exposure/Dose-Response Analyses of Efficacy and Safety

Favorite

7:00 AM – 5:00 PM MST

(M-119) Population Pharmacokinetic (popPK) of BMS-986012, a Novel Anti-Fucosyl-GM1 Monoclonal Antibody, in Patients with First-Line and Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Favorite

7:00 AM – 5:00 PM MST

(M-120) Quantitative Systems Toxicology Modeling of Otenaproxesul Liver Enzyme Elevations Leads to Prediction of Liver Safety for Acute Otenaproxesul Dosing

Favorite

7:00 AM – 5:00 PM MST

(M-121) Population Pharmacokinetics and Exposure-Response Analysis Supports Phase 2 Dose Selection for BMS-986288, a non-fucosylated anti-CTLA4 antibody Prodrug

Favorite

7:00 AM – 5:00 PM MST

(M-122) Overcome the Challenges of NONMEM PopPK Dataset for Late Stage Daily Dose Study

Favorite

7:00 AM – 5:00 PM MST

(M-123) Streamlining Dupilumab Nasal Polyposis Clinical Development Strategy: Leveraging Modeling and Biomarker Bridging for the Phase 3 Dose Selection

Favorite

7:00 AM – 5:00 PM MST

(M-124) Physiologically-based pharmacokinetic modeling approach to support eliglustat development for pediatric patients with Gaucher disease

Favorite

7:00 AM – 5:00 PM MST

(M-125) Explore the Impact of Pharmacological Target-Mediated Low Plasma Exposure in Lead Compound Selection in Drug Discovery – a Modeling Approach

Favorite

7:00 AM – 5:00 PM MST

(M-126) A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages

Favorite

7:00 AM – 5:00 PM MST

(M-127) Creating Cell-specific Computational Models of Stem Cell-derived Cardiomyocytes Using Optical Experiments

Favorite

7:00 AM – 5:00 PM MST

(M-128) Population Pharmacokinetic Analysis of Guselkumab in Adults with Moderately to Severely Active Crohn’s Disease

Favorite

7:00 AM – 5:00 PM MST

(M-129) Automating Translational Physiologically Based Pharmacokinetic Modeling with R and Simcyp: An Innovative Approach

Favorite

7:00 AM – 5:00 PM MST

(M-130) Across-species meta-analysis of methylprednisolone reversible metabolism and pharmacokinetics utilizing allometric and scaling model approaches

Favorite

7:00 AM – 5:00 PM MST

(M-131) Physiologically based pharmacokinetic modeling the reversible metabolism and tissue-specific partitioning of methylprednisolone and methylprednisone in rats

Favorite

7:00 AM – 5:00 PM MST

(M-132) Population Pharmacokinetics and Exposure-Response Relationship of Amivantamab in Combination with Carboplatin-Pemetrexed: Analyses from PAPILLON Supporting the Weight-Tiered Q3W Regimen

Favorite

7:00 AM – 5:00 PM MST

(M-133) Utilizing Opportunistic Clinical Study and Population-Based Pharmacometric Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients

Favorite

7:00 AM – 5:00 PM MST

(M-134) A Minimal Physiology-based Pharmacokinetics Model of Blood-Brain Barrier Transport for Monoclonal Antibodies Targeting the Transferrin Receptor

Favorite

7:00 AM – 5:00 PM MST

(M-135) A Bayesian disease progression model for Major Depressive Disorder

Favorite

7:00 AM – 5:00 PM MST

(M-136) A time-to-event model for Bronchopulmonary dysplasia based on real-world data

Favorite

7:00 AM – 5:00 PM MST

(M-137) A Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Model for Covalent Bruton Tyrosine Kinase Inhibitor TL-895

Favorite

7:00 AM – 5:00 PM MST

(M-138) Population cellular kinetics of idecabtagene vicleucel in patients with triple-class-exposed relapsed/refractory multiple myeloma

Favorite

7:00 AM – 5:00 PM MST

(M-139) Longitudinal modeling of a mechanism-based biomarker informs selection of golcadomide doses and dosing schedules for optimization in patients with relapsed or refractory non-Hodgkin lymphoma

Favorite

7:00 AM – 5:00 PM MST

(M-140) Nipocalimab pharmacokinetic/pharmacodynamic and exposure-response modeling in pregnancies at risk for early-onset severe (EOS) HDFN

Favorite

7:00 AM – 5:00 PM MST

(M-141) Population joint modeling of SARS-CoV-2 neutralizing titer dynamics after COVID-19 mRNA vaccine booster administration

Favorite

7:00 AM – 5:00 PM MST

(M-142) Evaluating concomitant medication use in cystic fibrosis patients using real-world data (RWD) to inform drug-drug interaction risk assessment and clinical trial design of GDC-6988

Favorite